PNC Financial Services Group’s Cidara Therapeutics CDTX Stock Holding History

PNC Financial Services Group’s Portfolio CDTX Stock Details CDTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-30	Closed	-$6.63K	–	5190
2025 Q4	$6.63K	Buy	30 +8	+36%	+$1.29K	﹤0.01%	4123
2025 Q3	$2.11K	Buy	+22	New	+$1.4K	﹤0.01%	4487

PNC Financial Services Group's CDTX Position: Q1 2026 in Review

PNC Financial Services Group sold out of Cidara Therapeutics (CDTX) in Q1 2026, closing a stake of 30 shares — an estimated $6.63K sold.

PNC Financial Services Group first reported a position in CDTX in Q3 2025 and held it in 2 quarters. The position peaked at $6.63K in Q4 2025. 0 funds tracked by Wall St. Rank hold CDTX as of Q1 2026.

PNC Financial Services Group reported no remaining Cidara Therapeutics position as of Q1 2026 after selling out during the quarter.
PNC Financial Services Group sold 30 Cidara Therapeutics shares in Q1 2026, an estimated $6.63K.
PNC Financial Services Group first reported a position in Cidara Therapeutics in Q3 2025 and held it in 2 quarters.
PNC Financial Services Group's Cidara Therapeutics position peaked at $6.63K in Q4 2025.
0 funds tracked by Wall St. Rank held Cidara Therapeutics as of Q1 2026.

Based on PNC Financial Services Group's 13F filing for Q1 2026, filed 8 May 2026.